11 Best Short-Term Stocks to Invest in

Page 4 of 10

7. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Performance 1 Year: -26.80%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) secures a spot in our list of 11 best short-term stocks to invest in. A definitive merger agreement announced in the first week of August drives a short-term surge in the stocks’ performance.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based oncology treatments. The company’s lead product, DANYELZA® (naxitamab-gqgk), is the first FDA-approved therapy for relapsed or refractory high-risk neuroblastoma in bone or bone marrow. Operating from New Jersey, the company also advances a robust pipeline of investigational cancer therapies.

On August 5, 2025, SERB Pharmaceuticals agreed to acquire Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) in an all-cash transaction valued at approximately $412 million. SERB will commence a tender offer to purchase all outstanding shares of the company’s common stock for $8.60 per share in cash. This offer represents an approximate 105% premium to Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’ closing share price on August 4, 2025, the last full trading day before the transaction announcement.

The acquisition includes DANYELZA, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’ lead commercial oncology asset. SERB intends to use it for broadening its existing Rare Oncology portfolio and expanding its investment in the U.S. market.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s stock price soared by 71.43% this week, gaining a dramatic rebound after a 26.80% yearly drop, making it one of the best short-term biotech investments.

Page 4 of 10